Pfizer will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live News

Pfizer announced the following change in senior management:Nilesh Pendse is appointed as Category Lead � Vaccines of the Company with effect from 01 February 2026. Pendse shall accordingly be a Senior Management Personnel of the Company effective the said date. Manikantan Seshadrinathan � Category Lead, Hospitals & Rare Disease will transition to another role within the Pfizer Group Companies effective 01 February 2026, and shall accordingly cease to be a Senior Management Personnel of the Company effective 31 January 2026. Prashant Mahalingam, Category Lead � Internal Medicine, will take up additional responsibility of the Hospitals Business of the Company and shall be redesignated as Category Lead � Internal Medicine & Hospitals, effective 01 February 2026. Powered by Capital Market - Live News

Pfizer has entered into an exclusive Supply and Marketing Agreement with Cipla for marketing and distribution of four brands of the Company, viz., Corex Dx, Corex LS, Dolonex, and Neksium for an initial period of 5 years.Powered by Capital Market - Live News

Net profit of Pfizer rose 19.37% to Rs 189.02 crore in the quarter ended September 2025 as against Rs 158.35 crore during the previous quarter ended September 2024. Sales rose 9.13% to Rs 642.34 crore in the quarter ended September 2025 as against Rs 588.59 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales642.34588.59 9 OPM %35.8032.15 - PBDT269.65230.22 17 PBT255.37215.23 19 NP189.02158.35 19 Powered by Capital Market - Live News

Pfizer will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live News